Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2013

View Archived Issues

Uncovering the mechanism behind the chemotherapeutic resistance that arises in glioblastoma

Preliminary phase I data presented for Shionogi's S-222611

NCI awards contract for melanoma diagnostic, U of Michigan offers new prostate cancer test

Scientists discover new antibodies binding to TGF-beta-1

Galaxy Biotech patents novel bispecific antibodies for cancer

DetectoGen presents new polypeptides as vaccines for leishmaniasis

Takeda Pharmaceutical synthesizes novel 5-HT2C receptor agonists

Japanese team prepares new BTK inhibitors

Asahi Kasei Pharma and Vernalis form autoimmune drug discovery collaboration

Scancell provides update on its drug discovery pipeline

Aerial BioPharma to accelerate development of ADX-N05

First demonstration of vaccine-mediated elimination of SIV infection

Diabetes agents found to improve behavioral and pathological signs of Alzheimer's disease

Tri-Institutional Therapeutics Discovery Institute and Takeda form drug discovery partnership

Xencor's XmAb-5871 advances to second phase of rheumatoid arthritis study

FDA and EMA accept OMS-302 marketing applications for review

Actavis completes acquisition of Warner Chilcott

Xention and Servier form cardiovascular collaboration for XEN-D0103

Moderna Therapeutics receives DARPA grant to develop messenger RNA therapeutics

Valneva enters into license agreement with International AIDS Vaccine Initiative

Heat Biologics files IND for HS-410 in bladder cancer

Amgen investigates metabolism across species of potent mTOR inhibitor

AZD-9291 shows promising activity in NSCLC patients

Vemurafenib shows promise for VEGFR-2 inhibitor-naive patients with PTC

Eisai gains European approval for use of antiepileptic agent in pediatric patients

StemCells gains IND clearance to expand clinical testing of HuCNS-SC in spinal cord injury to U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...